Alpha DNA Investment Management LLC Acquires Shares of 649 Repligen Co. (NASDAQ:RGEN)

Alpha DNA Investment Management LLC acquired a new stake in Repligen Co. (NASDAQ:RGEN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 649 shares of the biotechnology company’s stock, valued at approximately $124,000.

Several other institutional investors have also added to or reduced their stakes in the business. tru Independence LLC bought a new position in shares of Repligen in the fourth quarter valued at $260,000. Voya Financial Advisors Inc. raised its holdings in shares of Repligen by 2.8% in the fourth quarter. Voya Financial Advisors Inc. now owns 2,055 shares of the biotechnology company’s stock valued at $389,000 after purchasing an additional 55 shares during the last quarter. FormulaFolio Investments LLC purchased a new stake in shares of Repligen in the fourth quarter valued at about $661,000. Norges Bank purchased a new stake in shares of Repligen in the fourth quarter valued at about $80,850,000. Finally, Hsbc Holdings PLC raised its holdings in shares of Repligen by 71.8% in the fourth quarter. Hsbc Holdings PLC now owns 7,798 shares of the biotechnology company’s stock valued at $1,495,000 after purchasing an additional 3,260 shares during the last quarter. 84.33% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have recently commented on RGEN. SVB Leerink increased their target price on shares of Repligen from $220.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday, March 3rd. Craig Hallum raised their price objective on shares of Repligen from $245.00 to $251.00 and gave the stock a “buy” rating in a report on Thursday, February 25th. Finally, Zacks Investment Research downgraded shares of Repligen from a “strong-buy” rating to a “hold” rating and set a $200.00 price objective for the company. in a report on Tuesday, January 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $203.80.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 1,000 shares of Repligen stock in a transaction that occurred on Wednesday, March 3rd. The shares were sold at an average price of $205.00, for a total transaction of $205,000.00. Following the transaction, the director now directly owns 2,464 shares of the company’s stock, valued at $505,120. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jon Snodgres sold 3,545 shares of Repligen stock in a transaction that occurred on Thursday, March 4th. The stock was sold at an average price of $192.47, for a total transaction of $682,306.15. Following the transaction, the chief financial officer now directly owns 35,708 shares in the company, valued at $6,872,718.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,022 shares of company stock valued at $8,982,858. 1.70% of the stock is currently owned by company insiders.

RGEN stock opened at $201.31 on Thursday. The firm has a 50 day moving average of $199.72 and a 200-day moving average of $191.31. The company has a current ratio of 13.67, a quick ratio of 12.13 and a debt-to-equity ratio of 0.21. Repligen Co. has a 12 month low of $94.52 and a 12 month high of $228.84. The firm has a market capitalization of $11.03 billion, a P/E ratio of 245.50, a price-to-earnings-growth ratio of 4.18 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, February 23rd. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.21. Repligen had a net margin of 13.40% and a return on equity of 6.58%. The business had revenue of $108.65 million during the quarter, compared to analyst estimates of $93.89 million. Sell-side analysts predict that Repligen Co. will post 1.44 EPS for the current year.

Repligen Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Article: Why Invest in Dividend Achievers?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.